Serum Lipid Profile in Colorectal Cancer Patients with and without Synchronous Distant Metastases

Notarnicola, Maria; Altomare, D. F.; Correale, M.; Ruggieri, E; D’Attoma, Benedetta; Mastrosimini, Anna; Guerra, Vito; Caruso, Maria Gabriella

doi:10.1159/000086977

Cited by 60 publications

(49 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies to determine which metabolic disorder or combination of disorders in obese people increases their cancer risk have been inconclusive (3). Hypercholesterolemia, a common metabolic disorder in obese people, has been shown to increase cancer risk and substantial epidemiologic evidence links hypercholesterolemia to an increased risk of colorectal cancer (4). It was originally proposed that hypercholesterolemia exerts a systemic, conditional influence that affects immu-nosurveillance against colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells

et al. 2017

View full text Add to dashboard Cite

Obesity will soon surpass smoking as the most preventable cause of cancer. Hypercholesterolemia, a common comorbidity of obesity, has been shown to increase cancer risk, especially colorectal cancer. However, the mechanism by which hypercholesterolemia or any metabolic disorder increases cancer risk remains unknown. In this study, we show that hypercholesterolemia increases the incidence and pathologic severity of colorectal neoplasia in two independent mouse models. Hypocholesterolemia induced an oxidant stress-dependent increase in miR101c, which downregulated Tet1 in hematopoietic stem cells (HSC), resulting in reduced expression of genes critical to natural killer T cell (NKT) and γδ T-cell differentiation. These effects reduced the number and function of terminally differentiated NKT and γδ T cells in the thymus, the colon submucosa, and during early tumorigenesis. These results suggest a novel mechanism by which a metabolic disorder induces epigenetic changes to reduce lineage priming of HSC toward immune cells, thereby compromising immunosur-veillance against cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The fasting lipid profiles of Italian men and women with metastatic CRC (n = 22) had higher synchronous total cholesterol, LDL-cholesterol and LDL/HDL ratios compared to those without metastases (n = 62) (P = 0.03, 0.01, and 0.002, respectively) (Notarnicola, Altomare et al 2005). These results were independent of BMI.…”

Section: Breast Cancer Epidemiological Studies Showing a Higher Incimentioning

confidence: 78%

Lipoproteins and Cancer

Antalis¹,

Buhman²

2012

Lipoproteins - Role in Health and Diseases

View full text Add to dashboard Cite

“…Number of CRC patients, number of deaths due to CRC and to any cause, actuarial 5-year CRC-specific and relative survival probabilities, by TNM stages, type 2 diabetes mellitus status, and metformin and acetylsalicylic acid use. was associated to higher levels of LDL cholesterol over HDL cholesterol ratio, irrespective of sex and BMI (31). Additionally, the relationship between Serum Amyloid A and HDL particles can explain the inverse relationship between HDL cholesterol levels and cancer (32).…”

Section: Discussionmentioning

confidence: 94%

Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients

et al. 2018

View full text Add to dashboard Cite

Abstract. Metformin, the drug of choice in the treatment of type 2 diabetes mellitus (DM2), in addition to aspirin (ASA), the drug prescribed for cardioprotection of diabetic and non-diabetic patients, have an inhibitory effect on cancer cell survival. The present population-based study conducted in the province of Trieste (Italy), aimed to investigate the prevalence of DM2 in patients with colorectal adenocarcinoma (CRC) and survival for CRC in diabetic and nondiabetic patients. All permanent residents diagnosed with a CRC between 2004 and 2007 were ascertained through the regional health information system. CRC-specific and relative survival probabilities were computed for each group of patients defined by CRC stage, presence or absence of DM2 treated with metformin, and presence or absence of daily ASA therapy. A total of 515 CRC patients without DM2 and 156 with DM2 treated with metformin were enrolled in the study. At the time of CRC diagnosis, 71 (14%) nondiabetic and 39 (25%) diabetic patients were taking ASA daily. The five-year relative survival for stage III CRC was 101% [95% confidence interval (CI) =76-126] in the 18 patients with DM2 treated with metformin and ASA, 55% (95% CI=31-78) in the 23 without DM2 treated with ASA, 55% (95% CI=45-65) in the 150 without DM2 not taking ASA, and 29% (95% CI=13-45) in the 43 with DM2 treated with metformin, however not with ASA. The findings support the hypothesis of a possible inhibitory effect of metformin and ASA on CRC cells. Randomized controlled trials are required to verify this hypothesis.

show abstract

Serum Lipid Profile in Colorectal Cancer Patients with and without Synchronous Distant Metastases

Cited by 60 publications

References 33 publications

Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells

Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells

Lipoproteins and Cancer

Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients

Contact Info

Product

Resources

About